EFFECT OF ISOTRETINOIN ON ENDOGENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN HUMANS

被引:0
|
作者
WALLNOFER, AE
VANGRIENSVEN, JMT
SCHOEMAKER, HC
COHEN, AF
LAMBERT, W
KLUFT, C
MEIJER, P
KOOISTRA, T
机构
[1] UNIV HOSP LEIDEN,CTR HUMAN DRUG RES,2300 RC LEIDEN,NETHERLANDS
[2] STATE UNIV GHENT,MED BIOCHEM LAB,GHENT,BELGIUM
[3] TNO,IVVO,GAUBIUS LAB,LEIDEN,NETHERLANDS
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of isotretinoin on fibrinolysis was investigated in 10 healthy, male volunteers in a randomized, double-blind, crossover-designed study. Isotretinoin (40 mg) was administered in the morning and in the evening for 5 days. t-PA, u-PA and PAI-1 antigen and activity in plasma were measured every morning at 9 a. m. on days 1 to 4 and every 3 hours over 24 hours on day 5. Isotretinoin treatment had no significant stimulatory effect on endogenous t-PA antigen and activity in morning plasma samples nor on their circadian variation. Also, u-PA antigen levels did not change after isotretinoin treatment. Mean PAI-1 antigen and PAI activity in 9 a.m. plasma samples were non-significantly higher during isotretinoin than during placebo treatment. After treatment with isotretinoin a significant rise of fasting triglyceride plasma levels was observed as compared to placebo. The study shows that isotretinoin has no clinically significant effect on endogenous fibrinolysis.
引用
收藏
页码:1005 / 1008
页数:4
相关论文
共 50 条
  • [31] KINETIC-ANALYSIS OF THE INTERACTION BETWEEN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    MASSON, C
    ANGLESCANO, E
    BIOCHEMICAL JOURNAL, 1988, 256 (01) : 237 - 244
  • [32] PLASMA CHANGES OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 DURING CORONARY THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    OTTANI, F
    GALVANI, M
    NICOLINI, FA
    RONCHI, A
    FERRINI, D
    RUSTICALI, F
    CIRCULATION, 1993, 88 (04) : 320 - 320
  • [33] Plasminogen-activator inhibitor-1 in (PAI-1) gastric cancer
    Tabuchi, Y
    Nakamura, T
    Miyamura, K
    Nakae, S
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 447 - 450
  • [34] ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN DIC
    MATSUDA, T
    ASAKURA, H
    SAITO, M
    JOKAJI, H
    UOTANI, C
    KUMABASHIRI, I
    MORISHITA, E
    YAMAZAKI, M
    THROMBOSIS RESEARCH, 1991, 63 (02) : 269 - 269
  • [35] NEUTRALIZATION BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 OF MUTANTS OF TISSUE PLASMINOGEN-ACTIVATOR
    BERGUM, PW
    ERICKSON, LA
    ENZYME, 1988, 40 (2-3) : 122 - 129
  • [36] PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) LEVELS IN LIVER-DISEASES - SIGNIFICANCE OF COMPLEX-FORMATION WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR (TPA) IN PLASMA
    YOSHIKAWA, Y
    SAKATA, Y
    MAEKAWA, H
    TODA, G
    OKA, H
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 394 - 394
  • [37] DAYTIME FLUCTUATIONS IN BLOOD OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) AND ITS FAST-ACTING INHIBITOR (PAI-1)
    KLUFT, C
    JIE, AFH
    RIJKEN, DC
    VERHEIJEN, JH
    THROMBOSIS AND HAEMOSTASIS, 1988, 59 (02) : 329 - 332
  • [38] CORONARY THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA)
    SOBEL, BE
    THROMBOSIS AND HAEMOSTASIS, 1985, 54 (01) : 53 - 53
  • [39] THE RECEPTOR FOR TISSUE PLASMINOGEN-ACTIVATOR (T-PA) IN COMPLEX WITH ITS INHIBITOR, PAI-1, ON HUMAN HEPATOCYTES
    WING, LR
    BENNETT, B
    BOOTH, NA
    FEBS LETTERS, 1991, 278 (01): : 95 - 97
  • [40] Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome
    Kulwas, Arleta
    Lisewska, Beata
    Jundzill, Wieslaw
    Ruszkowska, Barbara
    Drewniak, Wanda
    Ruprecht, Zofia
    Gadomska, Grazyna
    Rosc, Danuta
    ADVANCES IN MEDICAL SCIENCES, 2017, 62 (01): : 87 - 91